Fig. 4
From: Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC
IRF9 reflects active IFN signaling pathways and a TRM signature. Top ten most significant Hallmark gene sets enriched in IRF9-positive tumors compared to IRF9 negative tumors pre-chemotherapy (a) and mid-chemotherapy (b). Both pre-chemotherapy and mid-chemotherapy samples compared based on pre-chemotherapy IRF9 staining. Width of bars indicate relative number of genes in the gene set. IFNα response signature enrichment pre-chemotherapy (c) and mid-chemotherapy (d). Tumor samples from IRF9-positive patients (n = 5) compared with IRF9-negative patients (n = 8) (limma “roast” gene set test). Statistic on x-axis is the gene wise moderated t-statistic computed by limma, and vertical bars represent t-statistic for each gene in the gene set
